Skip to main content
Premium Trial:

Request an Annual Quote

Agena Inks MassArray Distribution Deal for Middle East, Africa, Central Asia

NEW YORK — Agena Bioscience said on Wednesday that it has signed an exclusive distribution deal for its MassArray platform and related products in the Middle East, Africa, and Central Asia with Alliance Global.

According to Agena, the deal covers its MassArray mass spectrometry-based platform for genetic variant measurement, genetic testing applications on the system, and certain other products.

Additional terms were not disclosed.

"With their extensive biomedical distribution network, [Alliance Global] is an ideal partner to bring our high-throughput, low-cost, targeted genetic analysis solution to these emerging healthcare markets," Roman Haehn, senior VP of commercial operations at Agena, said in a statement.

Earlier this month, Agena launched a SARS-CoV-2 variant panel that runs on the MassArray system. The San Diego-based company also recently received Emergency Use Authorization from the US Food and Drug Administration for a MassArray SARS-CoV-2 test.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.